A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (NCT03178552)
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by a blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assay.
Who can join: Review the eligibility criteria below.
Location: UC Davis — Sacramento, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (164 Sites)
Showing the first 25 of 164 sites.
- UC Davis — Sacramento, California
- Rocky Mountain Cancer Center — Denver, Colorado
- SCRI Florida Cancer Specialists South — Fort Myers, Florida
- Florida Cancer Specialist, North Region — St. Petersburg, Florida
- University of Kentucky — Lexington, Kentucky
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
- Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
- Weill Cornell Medical College-New York Presbyterian Hospital — New York, New York
- Montefiore Medical Center — The Bronx, New York
- Oregon HSU — Portland, Oregon
- St. Luke's University Health network — Bethlehem, Pennsylvania
- Sarah Cannon Research Institute / Tennessee Oncology — Chattanooga, Tennessee
- Fundación CENIT para la Investigación en Neurociencias — Buenos Aires,
- Hospital Italiano — Buenos Aires,
- Hospital Britanico de Buenos Aires — Ciudad Autonoma Buenos Aires,
- Royal North Shore Hospital — St Leonards, New South Wales
- The Prince Charles Hospital — Chermside, Queensland
- Ashford Cancer Center Research — Kurralta Park, South Australia
- UZ Brussel — Brussels,
- Cliniques Universitaires St-Luc — Brussels,
- UZ Leuven Gasthuisberg — Leuven,
- Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda — Ijuí, Rio Grande do Sul
- Hospital Sao Lucas - PUCRS — Porto Alegre, Rio Grande do Sul
- Instituto do Cancer do Estado de Sao Paulo - ICESP — São Paulo, São Paulo
- Instituto Nacional de Cancer - INCa — Rio de Janeiro,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Small Cell Lung Cancer
- Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations — Birmingham, Alabama
- Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — La Jolla, California
- PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer — Houston, Texas
- Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer — Renton, Washington
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer — Boston, Massachusetts
- Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Chandler, Arizona
Explore by condition: All Non-Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.